Sponsor or institution

Clinical trials and research at Jiangsu Simcere Pharmaceutical Co., Ltd.

• 12Clinical trials
• 2Countries

Newest trials

All recruiting trials (12)

• SIM0689 in adults with advanced solid tumors

  This study tests SIM0689 by itself to see how safe it is and how the body handles it in adults with advanced solid tumors, using a dose-escalation approach and then expanding to specific tumor types at the chosen dose.

  Recruiting at 2 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Fuzhou, Fujian and 5 other locations · NCT07660432

• SIM0613 in people with advanced solid tumors

  A first-in-human, multicenter study testing SIM0613 to see if it is safe and tolerable and whether it has any effect in adults with advanced solid cancers.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07618260

• Suvemcitug plus trifluridine/tipiracil for refractory metastatic colorectal cancer

  This trial will test whether adding suvemcitug to trifluridine/tipiracil helps people with refractory metastatic colorectal cancer who have already had standard chemotherapy.

  Recruiting at 6 sites Phase 3 Jiangsu Simcere Pharmaceutical Co., Ltd. · Fuzhou, Fujian and 5 other locations · NCT07361003

• Testing how SIM0270 interacts with itraconazole, rifampin, and midazolam in healthy Chinese adults

  This test will see if SIM0270 changes blood levels of itraconazole, rifampin, or midazolam in healthy Chinese adults.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07357610

• Testing SIM0610 for adults with advanced solid tumors

  This will test whether SIM0610 is safe and can shrink tumors in adults with locally advanced or metastatic solid cancers such as non-small cell lung, colorectal, liver, and head and neck cancers.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Chongqing, Chongqing Municipality and 6 other locations · NCT07348211

• Phase I testing of SIM0609 in adults with advanced or metastatic solid tumors

  This trial tests SIM0609 to see if it is safe, tolerated, and can shrink tumors in adults with locally advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Beijing and 5 other locations · NCT07265921

• Phase 1 testing of SIM0686 for locally advanced or metastatic solid tumors

  This trial will try SIM0686 in adults with locally advanced or metastatic solid tumors to see if it is safe, how the body processes it, and whether it shows early signs of tumor control.

  Recruiting at 3 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 9 other locations · NCT07050459

• SIM0388 intraperitoneal treatment for malignant ascites

  This Phase I trial will test whether intraperitoneal Docetaxel polymeric micelles (SIM0388) can safely reduce malignant ascites in adults with advanced solid tumors who have exhausted or are not candidates for standard therapies.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07007988

• Evaluating SIM0508 for advanced solid tumors

  This study is testing a new treatment called SIM0508, alone and with another drug, to see if it can help people with advanced ovarian, prostate, breast, or pancreatic cancers.

  Recruiting at 2 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT06686745

• Evaluating SIM0500 for patients with relapsed or refractory multiple myeloma

  This study is testing a new drug called SIM0500 to see if it can help adults with relapsed or refractory multiple myeloma who haven't had success with other treatments.

  Recruiting at 16 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Phoenix, Arizona and 15 other locations · NCT06375044

• Investigating SIM0237 for treating Non-Muscle-Invasive Bladder Cancer

  This study is testing a new treatment called SIM0237 for people with Non-Muscle-Invasive Bladder Cancer who haven't responded to standard therapy, to see if it is safe and effective.

  Recruiting at 5 sites Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 13 other locations · NCT06186414

• Investigating SCR-6920 Capsule for Patients with Advanced Malignant Tumors

  This study is testing a new capsule called SCR-6920 to see if it is safe and can help patients with advanced tumors who haven't had success with other treatments.

  Recruiting Phase 1 Jiangsu Simcere Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT05528055

Quick answers

How many clinical trials run by Jiangsu Simcere Pharmaceutical Co., Ltd. are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (12 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 11, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →